331 related articles for article (PubMed ID: 21085591)
1. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
Currier JR; Ngauy V; de Souza MS; Ratto-Kim S; Cox JH; Polonis VR; Earl P; Moss B; Peel S; Slike B; Sriplienchan S; Thongcharoen P; Paris RM; Robb ML; Kim J; Michael NL; Marovich MA
PLoS One; 2010 Nov; 5(11):e13983. PubMed ID: 21085591
[TBL] [Abstract][Full Text] [Related]
2. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
Vasan S; Schlesinger SJ; Chen Z; Hurley A; Lombardo A; Than S; Adesanya P; Bunce C; Boaz M; Boyle R; Sayeed E; Clark L; Dugin D; Boente-Carrera M; Schmidt C; Fang Q; LeiBa ; Huang Y; Zaharatos GJ; Gardiner DF; Caskey M; Seamons L; Ho M; Dally L; Smith C; Cox J; Gill D; Gilmour J; Keefer MC; Fast P; Ho DD
PLoS One; 2010 Jan; 5(1):e8816. PubMed ID: 20111599
[TBL] [Abstract][Full Text] [Related]
4. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
Ramanathan VD; Kumar M; Mahalingam J; Sathyamoorthy P; Narayanan PR; Solomon S; Panicali D; Chakrabarty S; Cox J; Sayeed E; Ackland J; Verlinde C; Vooijs D; Loughran K; Barin B; Lombardo A; Gilmour J; Stevens G; Smith MS; Tarragona-Fiol T; Hayes P; Kochhar S; Excler JL; Fast P
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1107-16. PubMed ID: 19943789
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
García F; Bernaldo de Quirós JC; Gómez CE; Perdiguero B; Nájera JL; Jiménez V; García-Arriaza J; Guardo AC; Pérez I; Díaz-Brito V; Conde MS; González N; Alvarez A; Alcamí J; Jiménez JL; Pich J; Arnaiz JA; Maleno MJ; León A; Muñoz-Fernández MA; Liljeström P; Weber J; Pantaleo G; Gatell JM; Plana M; Esteban M
Vaccine; 2011 Oct; 29(46):8309-16. PubMed ID: 21907749
[TBL] [Abstract][Full Text] [Related]
7. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
[TBL] [Abstract][Full Text] [Related]
8. Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.
Nilsson C; Godoy-Ramirez K; Hejdeman B; Bråve A; Gudmundsdotter L; Hallengärd D; Currier JR; Wieczorek L; Hasselrot K; Earl PL; Polonis VR; Marovich MA; Robb ML; Sandström E; Wahren B; Biberfeld G
AIDS Res Hum Retroviruses; 2014 Mar; 30(3):299-311. PubMed ID: 24090081
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.
Vasan S; Schlesinger SJ; Huang Y; Hurley A; Lombardo A; Chen Z; Than S; Adesanya P; Bunce C; Boaz M; Boyle R; Sayeed E; Clark L; Dugin D; Schmidt C; Song Y; Seamons L; Dally L; Ho M; Smith C; Markowitz M; Cox J; Gill DK; Gilmour J; Keefer MC; Fast P; Ho DD
PLoS One; 2010 Jan; 5(1):e8617. PubMed ID: 20111582
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.
Ake JA; Schuetz A; Pegu P; Wieczorek L; Eller MA; Kibuuka H; Sawe F; Maboko L; Polonis V; Karasavva N; Weiner D; Sekiziyivu A; Kosgei J; Missanga M; Kroidl A; Mann P; Ratto-Kim S; Anne Eller L; Earl P; Moss B; Dorsey-Spitz J; Milazzo M; Laissa Ouedraogo G; Rizvi F; Yan J; Khan AS; Peel S; Sardesai NY; Michael NL; Ngauy V; Marovich M; Robb ML
J Infect Dis; 2017 Nov; 216(9):1080-1090. PubMed ID: 28968759
[TBL] [Abstract][Full Text] [Related]
11. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
Guardo AC; Gómez CE; Díaz-Brito V; Pich J; Arnaiz JA; Perdiguero B; García-Arriaza J; González N; Sorzano COS; Jiménez L; Jiménez JL; Muñoz-Fernández MÁ; Gatell JM; Alcamí J; Esteban M; López Bernaldo de Quirós JC; García F; Plana M;
PLoS One; 2017; 12(10):e0186602. PubMed ID: 29065142
[TBL] [Abstract][Full Text] [Related]
12. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
Sandström E; Nilsson C; Hejdeman B; Bråve A; Bratt G; Robb M; Cox J; Vancott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G;
J Infect Dis; 2008 Nov; 198(10):1482-90. PubMed ID: 18808335
[TBL] [Abstract][Full Text] [Related]
13. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
Keefer MC; Gilmour J; Hayes P; Gill D; Kopycinski J; Cheeseman H; Cashin-Cox M; Naarding M; Clark L; Fernandez N; Bunce CA; Hay CM; Welsh S; Komaroff W; Hachaambwa L; Tarragona-Fiol T; Sayeed E; Zachariah D; Ackland J; Loughran K; Barin B; Cormier E; Cox JH; Fast P; Excler JL
PLoS One; 2012; 7(8):e41936. PubMed ID: 22870265
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
[TBL] [Abstract][Full Text] [Related]
15. Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.
Joachim A; Bauer A; Joseph S; Geldmacher C; Munseri PJ; Aboud S; Missanga M; Mann P; Wahren B; Ferrari G; Polonis VR; Robb ML; Weber J; Tatoud R; Maboko L; Hoelscher M; Lyamuya EF; Biberfeld G; Sandström E; Kroidl A; Bakari M; Nilsson C; McCormack S
PLoS One; 2016; 11(5):e0155702. PubMed ID: 27192151
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
Omosa-Manyonyi G; Mpendo J; Ruzagira E; Kilembe W; Chomba E; Roman F; Bourguignon P; Koutsoukos M; Collard A; Voss G; Laufer D; Stevens G; Hayes P; Clark L; Cormier E; Dally L; Barin B; Ackland J; Syvertsen K; Zachariah D; Anas K; Sayeed E; Lombardo A; Gilmour J; Cox J; Fast P; Priddy F
PLoS One; 2015; 10(5):e0125954. PubMed ID: 25961283
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
Koch T; Dahlke C; Fathi A; Kupke A; Krähling V; Okba NMA; Halwe S; Rohde C; Eickmann M; Volz A; Hesterkamp T; Jambrecina A; Borregaard S; Ly ML; Zinser ME; Bartels E; Poetsch JSH; Neumann R; Fux R; Schmiedel S; Lohse AW; Haagmans BL; Sutter G; Becker S; Addo MM
Lancet Infect Dis; 2020 Jul; 20(7):827-838. PubMed ID: 32325037
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E;
PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299
[TBL] [Abstract][Full Text] [Related]
19. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
Peters BS; Jaoko W; Vardas E; Panayotakopoulos G; Fast P; Schmidt C; Gilmour J; Bogoshi M; Omosa-Manyonyi G; Dally L; Klavinskis L; Farah B; Tarragona T; Bart PA; Robinson A; Pieterse C; Stevens W; Thomas R; Barin B; McMichael AJ; McIntyre JA; Pantaleo G; Hanke T; Bwayo J
Vaccine; 2007 Mar; 25(11):2120-7. PubMed ID: 17250931
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.
Hayton EJ; Rose A; Ibrahimsa U; Del Sorbo M; Capone S; Crook A; Black AP; Dorrell L; Hanke T
PLoS One; 2014; 9(7):e101591. PubMed ID: 25007091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
